tiprankstipranks
Advertisement
Advertisement

GANX Stock Latest News

Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
RatingsShrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained
21d ago
GANX
Gain Therapeutics presents data from Phase 1b study of GT-02287
PremiumThe Fly
Gain Therapeutics presents data from Phase 1b study of GT-02287
21d ago
GANX
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
PremiumCompany Announcements
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
21d ago
8K
GANX
Is GANX a Buy, Before Earnings?
PremiumPre-Earnings
Is GANX a Buy, Before Earnings?
1M ago
GANX
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
PremiumRatings
Buy Rating Reaffirmed on Encouraging GT-02287 Parkinson’s Data and Upcoming Catalysts; 12‑Month Price Target Maintained at $7
1M ago
GANX
Gain Therapeutics price target lowered to $8 from $10 at Roth Capital
PremiumThe FlyGain Therapeutics price target lowered to $8 from $10 at Roth Capital
1M ago
GANX
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
Premium
The Fly
Gain Therapeutics reports Q1 EPS (13c), consensus (14c)
1M ago
GANX
Gain Therapeutics management to meet with Maxim
Premium
The Fly
Gain Therapeutics management to meet with Maxim
2M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
PremiumRatings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Parkinson’s Data and Diversified GCase Pipeline Support $8 Target
3M ago
GANX
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
PremiumThe Fly
Gain Therapeutics reports Q4 EPS (61c), consensus (14c)
3M ago
GANX
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
PremiumCompany Announcements
Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data
3M ago
8K
GANX
Gain announces presentations on Phase 1b clinical study of GT-02287
PremiumThe Fly
Gain announces presentations on Phase 1b clinical study of GT-02287
3M ago
GANX
Gain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
PremiumPre-EarningsGain Therapeutics, Inc. (GANX) Q4 Earnings Cheat Sheet
3M ago
GANX
Gain Therapeutics provides regulatory update on GT-02287
Premium
The Fly
Gain Therapeutics provides regulatory update on GT-02287
3M ago
GANX
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
Premium
Ratings
Buy Rating on Gain Therapeutics Driven by Validated Mechanism, Compelling Phase 1b Parkinson’s Data, and Attractive Risk‑Reward Despite Near‑Term Financing Needs
5M ago
GANX
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
PremiumRatings
Maintaining Buy on Gain Therapeutics: Strong GCase Biology, Validated GluSph Biomarker, and Favorable Risk-Reward for GT-02287 in Parkinson’s Disease
5M ago
GANX
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
PremiumThe Fly
Gain Therapeutics provides additional data from Phase 1b study of GT-02287
5M ago
GANX
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
PremiumRatings
Gain Therapeutics: Attractive Upside on GT-02287 Parkinson’s Data and Upcoming KOL Catalyst Supports Buy Rating
6M ago
GANX
Gain Therapeutics holds a conference call
PremiumThe Fly
Gain Therapeutics holds a conference call
6M ago
GANX
Gain Therapeutics price target raised to $10 from $6 at Roth Capital
PremiumThe FlyGain Therapeutics price target raised to $10 from $6 at Roth Capital
6M ago
GANX
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
Premium
Ratings
Clinical and Mechanistic De-Risking of GT-02287 Underpins Buy Rating on Gain Therapeutics (GANX)
6M ago
GANX
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
Premium
Ratings
Reiterating Buy on Gain Therapeutics: Promising GT-02287 Biomarker Data and Efficient Clinical Path Support Disease‑Modifying Potential in Parkinson’s
6M ago
GANX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >